Galway-led research is advancing an implant platform designed to deliver emerging therapies directly to the ovarian cancer environment while enabling repeated treatment and disease monitoring.

Researchers at the University of Galway have developed a flexible implant designed to support more targeted delivery of next-generation therapies for ovarian cancer, strengthening Ireland's position in advanced drug delivery and medical-device research. The Silicon Republic report on the Galway-led research details the project involving CÚRAM, the Research Ireland Centre for Medical Devices, alongside collaborators from the University of Minnesota, Massachusetts Institute of Technology and the Wyss Institute.

The implant is designed to sit inside the peritoneal cavity, where ovarian cancer predominantly occurs, with its flexible and porous material conforming to the body's internal contours. An external port connected through the skin would allow therapeutic agents to be introduced repeatedly without requiring further surgery.

For the pharma industry, the technology is significant because it could provide a new delivery mechanism for emerging cell and biologic therapies. Rather than relying exclusively on systemic administration, the platform is being developed to bring therapies closer to the disease site while providing an opportunity to monitor how the local environment responds.

The underlying research has been published in the scientific journal Device, with preclinical testing showing that the implant remained functional for up to 70 days without implant-related complications. The CÚRAM research announcement describes the platform as a replenishable system capable of supporting repeated delivery of therapeutic agents while also allowing sampling from the peritoneal cavity.

The potential to repeatedly deliver living cell therapies is particularly relevant as pharmaceutical companies continue to develop increasingly sophisticated immunotherapies and cell-based treatments. The researchers believe the platform could also accommodate non-cell-based therapies, creating potential applications beyond a single therapeutic approach.

The monitoring capability is another important element. By providing access to the local treatment environment, the technology could eventually help researchers assess how immune cells are performing and whether tumours are responding, potentially supporting more responsive approaches to treatment development.

The project also demonstrates the importance of collaboration between pharmaceutical research, biomedical engineering and medical-device development. CÚRAM's involvement brings together expertise in implantable technologies with research in oncology and advanced therapeutic delivery, while the international collaboration broadens the technical and translational expertise behind the project.

For Ireland, the research adds to a growing body of work connecting academic research with the development of advanced therapies and medical technologies. The University of Galway's research announcement identifies the project as part of the university's wider research activity in medical devices and cancer treatment.

The findings remain at the preclinical research stage, meaning further development and testing will be required before the technology could be considered for clinical use. However, the ability to combine localised therapeutic delivery with ongoing monitoring provides a potentially useful platform for future cancer treatment research.

For the sector, the Galway project demonstrates how medical-device innovation can help address delivery challenges associated with next-generation therapies. As cell and biologic treatments become more sophisticated, technologies that enable precise delivery, repeated administration and treatment monitoring could become increasingly important to translating pharmaceutical research into clinical applications.

Source: Silicon Republic / CÚRAM / University of Galway